150 related articles for article (PubMed ID: 29534964)
1. Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming.
Ma L; Cheng Q
Biochem Biophys Res Commun; 2018 Apr; 498(4):912-917. PubMed ID: 29534964
[TBL] [Abstract][Full Text] [Related]
2. 6PGD inhibition sensitizes hepatocellular carcinoma to chemotherapy via AMPK activation and metabolic reprogramming.
Chen H; Wu D; Bao L; Yin T; Lei D; Yu J; Tong X
Biomed Pharmacother; 2019 Mar; 111():1353-1358. PubMed ID: 30841449
[TBL] [Abstract][Full Text] [Related]
3. 6PGD Upregulation is Associated with Chemo- and Immuno-Resistance of Renal Cell Carcinoma via AMPK Signaling-Dependent NADPH-Mediated Metabolic Reprograming.
Cao J; Sun X; Zhang X; Chen D
Am J Med Sci; 2020 Sep; 360(3):279-286. PubMed ID: 32829780
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of 6-Phosphogluconate Dehydrogenase Reverses Epirubicin Resistance Through Metabolic Reprograming in Triple-Negative Breast Cancer Cells.
Xu J; Ren G; Cheng Q
Technol Cancer Res Treat; 2023; 22():15330338231190737. PubMed ID: 37559469
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting 6-phosphogluconate dehydrogenase selectively targets breast cancer through AMPK activation.
Yang X; Peng X; Huang J
Clin Transl Oncol; 2018 Sep; 20(9):1145-1152. PubMed ID: 29340974
[TBL] [Abstract][Full Text] [Related]
6. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
[TBL] [Abstract][Full Text] [Related]
7. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
Wang W; Zhou J; Zhao L; Chen S
Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming.
Bhanot H; Weisberg EL; Reddy MM; Nonami A; Neuberg D; Stone RM; Podar K; Salgia R; Griffin JD; Sattler M
Oncotarget; 2017 Sep; 8(40):67639-67650. PubMed ID: 28978059
[TBL] [Abstract][Full Text] [Related]
9. KLF5 influences cell biological function and chemotherapy sensitivity through the JNK signaling pathway in anaplastic thyroid carcinoma.
Wang Z; Qiu X; Zhang H; Li W
J Biochem Mol Toxicol; 2020 May; 34(5):e22469. PubMed ID: 32173973
[TBL] [Abstract][Full Text] [Related]
10. 6-Phosphogluconate dehydrogenase fuels multiple aspects of cancer cells: From cancer initiation to metastasis and chemoresistance.
Sarfraz I; Rasul A; Hussain G; Shah MA; Zahoor AF; Asrar M; Selamoglu Z; Ji XY; Adem Ş; Sarker SD
Biofactors; 2020 Jul; 46(4):550-562. PubMed ID: 32039535
[TBL] [Abstract][Full Text] [Related]
11. miR-27b-3p is Involved in Doxorubicin Resistance of Human Anaplastic Thyroid Cancer Cells via Targeting Peroxisome Proliferator-Activated Receptor Gamma.
Xu Y; Han YF; Ye B; Zhang YL; Dong JD; Zhu SJ; Chen J
Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):670-677. PubMed ID: 29924913
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting 6-phosphogluconate dehydrogenase enhances chemotherapy efficacy in cervical cancer via AMPK-independent inhibition of RhoA and Rac1.
Guo H; Xiang Z; Zhang Y; Sun D
Clin Transl Oncol; 2019 Apr; 21(4):404-411. PubMed ID: 30182212
[TBL] [Abstract][Full Text] [Related]
13. miR-381-3p attenuates doxorubicin resistance in human anaplastic thyroid carcinoma via targeting homeobox A9.
Zhang Y; Li K; Wang W; Han J
Int J Exp Pathol; 2021 Aug; 102(4-5):209-217. PubMed ID: 34719830
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells
Xiong L; Lin XM; Nie JH; Ye HS; Liu J
Nanotheranostics; 2021; 5(2):143-154. PubMed ID: 33457193
[No Abstract] [Full Text] [Related]
15. Small interfering RNA (siRNA) against Slug induces apoptosis and sensitizes human anaplastic thyroid carcinoma cells to doxorubicin.
Pan Y; Liu P; Chen D; Dou L
Cancer Biomark; 2017; 18(4):357-366. PubMed ID: 28128736
[TBL] [Abstract][Full Text] [Related]
16. Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinoma.
Geng M; Yang Y; Cao X; Dang L; Zhang T; Zhang L
Biochem Biophys Res Commun; 2019 Dec; 520(3):544-550. PubMed ID: 31615655
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine phosphorylation activates 6-phosphogluconate dehydrogenase and promotes tumor growth and radiation resistance.
Liu R; Li W; Tao B; Wang X; Yang Z; Zhang Y; Wang C; Liu R; Gao H; Liang J; Yang W
Nat Commun; 2019 Mar; 10(1):991. PubMed ID: 30824700
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Mnk-eIF4E pathway sensitizes the efficacy to chemotherapy in anaplastic thyroid cancer.
Hu K; Zhang J; Yu M; Xiong C
Future Oncol; 2017 Mar; 13(6):489-498. PubMed ID: 27785922
[TBL] [Abstract][Full Text] [Related]
19. LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway.
Wang XM; Liu Y; Fan YX; Liu Z; Yuan QL; Jia M; Geng ZS; Gu L; Lu XB
Cancer Biol Ther; 2018 Jul; 19(7):590-597. PubMed ID: 29561707
[TBL] [Abstract][Full Text] [Related]
20. Antimalarial drug artesunate is effective against chemoresistant anaplastic thyroid carcinoma via targeting mitochondrial metabolism.
Ma L; Fei H
J Bioenerg Biomembr; 2020 Apr; 52(2):123-130. PubMed ID: 32036542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]